CT 032 - CARSgen
Alternative Names: Anti-CD19 chimeric antigen receptor T cell therapy - CARsgen; CAR-CD19 T cells - CARsgen; CD19 Redirected Autologous Cells - CARsgen; CT-032 - CARSgen; CT032 CAR-CD19 T cells - CARsgenLatest Information Update: 18 Mar 2024
At a glance
- Originator CARsgen
- Developer CARsgen; Renji Hospital
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Non-Hodgkin's lymphoma
- No development reported Lymphoid leukaemia
Most Recent Events
- 27 May 2021 CARsgen Therapeutics completes the phase I/II trial in Non-Hodgkin's B Cell Lymphoma (Refractory metastatic disease, Second-line therapy or greater) in China (NCT03994913)
- 28 Feb 2020 No recent reports of development identified for phase-I development in Lymphoid-leukaemia in China (IV)
- 27 Sep 2019 Phase-I/II clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater, Refractory metastatic disease) in China (IV) (NCT03994913)